

1 **Tuning Hapten Density on Protein Conjugates Programs**

2 **Vaccine Immunity via Carrier Protein Processing**

3 Rui Liu^{1, & ,#}, Xuezhi Yu^{1, #}, Yingjie Zhang¹, Bochen Lv¹, Li Nan¹, Linhui Zhang¹,

4 Yinkun Liu¹, Fanjian Zhang², Jing Zhang¹, Kai Wen¹, Jianzhong Shen^{1, *}, Zhanhui

5 Wang^{1, *}

6 *¹State Key Laboratory of Veterinary Public Health and Safety, Beijing Key Laboratory*

7 *of Detection Technology for Animal Derived Food Safety, College of Veterinary*

8 *Medicine, China Agricultural University, 100193, Beijing, People's Republic of China*

9 *²Department of Animal Science and Technology, Beijing Vocational College of*

10 *Agriculture, 102442, Beijing, People's Republic of China*

11

12 # These authors contributed equally to this work

13 & present institution: Department of Animal Science and Technology, Beijing

14 Vocational College of Agriculture, 102442, Beijing, People's Republic of China

15 *Corresponding authors: Jianzhong Shen (JZ Shen), and Zhanhui Wang (ZH Wang)

16 Tel: +86-10-6273 4565,

17 Fax: +86-10-6273 1032

18 *Corresponding authors: E-mail: sjz@cau.edu.cn; wangzhanhui@cau.edu.cn

19

Supplementary Tables and Figures

	Legends	Pages
Supplementary Fig. 1	Supplementary Fig. 1 Characterization of hapten density and protein structure of AMDH-BSA and AMDH-OVA. (A, B) Molecular weight characterization of OVA and AMDH-OVA conjugates by MALDI-TOF/MS, with the corresponding hapten densities summarized in Table 1. (C) Correlation between hapten density calculated by MOLDI-TOF/MS result and feed ratio used during synthesis. Data are fitted to a linear regression ($R^2=0.9959$). (D) The standard curve of amino groups occupation in natural BSA was detected by the TNBS method, plotted as OD ₄₂₀ versus percentage of consumed amino groups. (E) SDS-PAGE detection of AMDH-BSA conjugates C1, C3, C5, C6, and C8 alongside BSA and molecular weight markers. (F) Comparisons of secondary structure of AMDH-BSA conjugates C1, C3, C5, C6, and C8 by CD spectrum, showing α -helix, β -sheet, β -turn, and random coil percentages.	S8
Supplementary Fig. 2	Supplementary Fig. 2 Influence of AMDH-BSA conjugates with varied hapten densities on cathepsin S-mediated BSA digestion <i>in vitro</i> . (A) Peptide coverage maps of BSA and AMDH-BSA conjugates C1, C3, C5, C6, and C8 after enzymatic degradation with cathepsin S. Each identified peptide is represented as a horizontal line mapped onto the BSA amino acid sequence. The y-axis height varies with the abundance of detected peptides, while the x-axis corresponds to amino acid positions in BSA. (B) Heat map of PSMs differences for the LKH556-571 peptide cluster of BSA. The peptide sequence shown corresponds to the AMDH-modified peptide containing the modification (C18H30NO) on the lysine residue. PSMs were quantified with posterior error probability (PEP) values of <0.01. Two independent experiments are labeled as “-1” and “-2” after each sample name.	S9
Supplementary Fig. 3	Supplementary Fig. 3 Effect of hapten density on the secondary structure and hydrogen bonding interactions of BSA by 200 ns MD simulations. (A) Secondary structure composition of BSA and AMDH-BSA conjugates C1, C3, C5, C6 over the 200 ns simulation trajectory, showing percentages of α -helix, β -sheet, β -turn, and random coil at 0, 50, 100, 150, and 200 ns. (B) Number of hydrogen bonds in BSA and AMDH-BSA conjugates C1, C3, C5, and C6 over the 200 ns simulation trajectory.	S10
Supplementary Fig. 4	Supplementary Fig. 4 Influence of AMDH-BSA conjugates with varied hapten densities on CD4 ⁺ /CD8 ⁺ T cells ratio and splenocytes proliferation. (A) CD4 ⁺ /CD8 ⁺ T cells ratio in splenic lymphocytes from mice immunized with C1, C3, C5, C6, C8, or PBS. (B) OD ₄₅₀ of	S11

	splenocytes proliferation after treatment with 50 µg/mL AMDH-BSA conjugates C1, C3, C5, C6, C8, or PBS for 72 h; (C) OD ₄₅₀ of splenocyte proliferation after treatment with AMDH-BSA conjugates in the presence of 10 µg/mL ConA (T cell stimulant). (D) OD ₄₅₀ of splenocyte proliferation after treatment with AMDH-BSA conjugates in the presence of 12.5 µg/mL LPS (B cell stimulant). * p < 0.05, * * p < 0.005, * * * p < 0.001, * * * *p < 0.0001. Means and standard deviations are displayed (n=3 mice/group). Statistical significance was determined by ANOVA with multiple comparison testing among all groups except the PBS group.	
Supplementary Fig. 5	Supplementary Fig. 5 AMDH-BSA-specific, BSA-specific, and AMDH-specific antibody titers of antisera from vaccinated mice on (A) day 7, (B) day 21 and (C) day 49. (D) AMDH-specific IgG3 and IgA subclasses OD ₄₅₀ values in antisera from immunized mice on day 28, determined by nc-ELISA. Means and standard deviations are displayed (n=6-8 mice/group).	S12
Supplementary Fig. 6	Supplementary Fig. 6 Influence of hapten density on immune repertoire and transcriptional programs in bulk RNA-seq. (A) Volcano plots of differential expression analysis for C1 versus BSA, C3 versus BSA, C8 versus BSA, C8 versus C1, C8 versus C3. Significantly upregulated and downregulated genes are shown in red and blue, respectively (n=3 mice per group). (B) Top 20 GO analysis for C8 versus C1 (left) and C8 versus C3 (right).	S13
Supplementary Fig. 7	Supplementary Fig. 7 Synthesis and characterization of hapten AMDH. (A) Synthetic routes of AMDH. Reaction conditions: (i) ethyl bromoacetate, K ₂ CO ₃ , DMF, 60 °C, 16 h; (ii) NaOH, EtOH/H ₂ O, 1 h, then HCl to pH 5. (B) The mass spectrum of AMDH. The observed molecular ion [M-H] ⁻ at m/z 292 is consistent with the calculated mass (C ₁₈ H ₃₀ NO ₂ ⁻ , 292). (C) The ¹ H NMR spectrum of AMDH in DMSO-d ₆ . (D) The ¹³ C NMR spectrum of AMDH in DMSO-d ₆ .	S14
Supplementary Table 1	Molecular descriptors of AMD and AMDH	S15
Supplementary Table 2	Analysis of hapten density in AMDH-BSA conjugates by TNBS method	S16
Supplementary Table 3	The information on immunization procedures	S17

21

22

1. Buffers

The common buffer solutions used in the experiment are listed:

(1) Phosphate buffer solution (PBS buffer, 0.01 mol L^{-1} , pH 7.4);

(2) Coating buffer (0.05 mol L^{-1} carbonate buffer, pH 9.6);

(3) Blocking buffer (2% skim milk powder (w/v));

(4) Washing buffer (PBST, 0.01 mol L^{-1} PBS buffer with 0.05% Tween-20 (v/v), pH 7.2);

(5) Goat anti-mouse IgG (HRP labeled) dilution buffer (0.01 mol L^{-1} PBS buffer containing 5% albumin (w/v));

(6) Stopping reagent ($2\text{ mol/L H}_2\text{SO}_4$).

2. Determination of antibody titer

The antibody titers of the mouse antisera were measured by using nc-ELISA: 96-well microplates were coated overnight at $4\text{ }^{\circ}\text{C}$ with $100\text{ }\mu\text{L/well}$ coating antigens (BSA, C4 or AMDH-OVA) at $2\text{ }\mu\text{g/mL}$ in coating buffer. To eliminate non-specific binding interference, the plate was blocked with $150\text{ }\mu\text{L/well}$ blocking buffer for 2 hours at $37\text{ }^{\circ}\text{C}$ and washed three times with washing buffer. Then, $100\text{ }\mu\text{L/well}$ of antisera serially diluted 2-fold was added and incubated at $37\text{ }^{\circ}\text{C}$ for 1 h. After washing three times with washing buffer to remove unbound antibodies, $100\text{ }\mu\text{L/well}$ of HRP-labeled goat anti-mouse IgG (diluted at 1:5000) was added and incubated at $37\text{ }^{\circ}\text{C}$ for 30 min, followed by four washes. Subsequently, $100\text{ }\mu\text{L/well}$ of substrate/chromogen solution was added to each well and incubated at $37\text{ }^{\circ}\text{C}$ for 15 min. The reaction was stopped by adding $50\text{ }\mu\text{L/well}$ of $2\text{ M H}_2\text{SO}_4$. BSA-specific,

AMDH-BSA-specific, and AMDH-specific antibody titers were defined as the reciprocal of the highest serum dilution yielding an OD_{450nm} value greater than the mean plus three standard deviations (mean + 3SD) of the control wells


3. Determination of antibody subclass

Antibody subclasses in mouse antisera were determined using a ncELISA. Briefly, 96-well microplates were coated overnight at 4 °C for 16 h with 100 µL/well of coating antigen (AMDH-OVA and BSA) at 2 µg/mL in coating buffer. Plates were blocked with 150 µL/well blocking buffer for 2 h at 37 °C and washed three times with washing buffer. Mouse antisera from all immunization groups were uniformly diluted to 1:1600, and 100 µL/well was added and incubated at 37 °C for 1 h. After washing three times, 100 µL/well of HRP-conjugated, isotype-specific goat anti-mouse secondary antibodies (IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA; all diluted 1:2000) were added and incubated at 37°C for 1 h followed by four washes. Subsequently, 100 µL/well of substrate/chromogen solution was added and incubated at 37 °C for 15 min, and the reaction was stopped with 50 µL/well of 2 M H₂SO₄. The OD_{450nm} values were used to quantify the relative levels of each antibody subclass in the antisera.

4. Determination of antibody affinity

Antibody affinity of the mouse antisera was measured by using ic-ELISA: The 96-well microplates were coated with 100 µL/well of AMDH-OVA in coating buffer at 1 µg/mL or 0.2 µg/mL and incubated overnight at 4 °C for 16 h. After blocking, 50 µL/well of AMD standard at 100 µg/L and serially diluted antisera were added and incubated at 37 °C for 30 min. Plates were washed, followed by the addition of 100

68 $\mu\text{L}/\text{well}$ of HRP-conjugated goat anti-mouse IgG (1:5000) and incubated at 37 °C for
69 30 min. After discarding wash buffer, the substrate/chromogen was added and
70 incubated for 15 min. Then, the reaction was stopped by 50 $\mu\text{L}/\text{well}$ of H_2SO_4 , and the
71 OD_{450} were measured. Serum dilutions yielding OD_{450} values within 1.5-2.0 were
72 selected to calculate inhibition rates for antibody affinity evaluation. The lowest
73 inhibition rate obtained for each antisera under its optimal coating antigen
74 concentration and antisera dilution was used for subsequent statistical analyses.



75

76 Supplementary Fig. 1 Characterization of hapten density and protein structure of

77 AMDH-BSA and AMDH-OVA. (A and B) Molecular weight characterization of OVA

78 and AMDH-OVA conjugates by MALDI-TOF/MS, with the corresponding hapten

79 densities summarized in Table 1. (C) Correlation between hapten density calculated

80 by MOLDI-TOF/MS result and feed ratio used during synthesis. Data are fitted to a

81 linear regression ($R^2 = 0.9959$). (D) The standard curve of amino groups occupation in


82 natural BSA was detected by the TNBS method, plotted as OD_{420} versus percentage of

83 consumed amino groups. (E) SDS-PAGE detection of AMDH-BSA conjugates C1, C3,


84 C5, C6, and C8 alongside BSA and molecular weight markers. (F) Comparisons of

85 secondary structure of AMDH-BSA conjugates C1, C3, C5, C6, and C8 by CD

86 spectrum, showing α -helix, β -sheet, β -turn, and random coil percentages.




Supplementary Fig. 2 Influence of AMDH-BSA conjugates with varied hapten densities on cathepsin S-mediated BSA digestion *in vitro*. (A) Peptide coverage maps of BSA and AMDH-BSA conjugates C1, C3, C5, C6, and C8 after enzymatic degradation with cathepsin S. Each identified peptide is represented as a horizontal line mapped onto the BSA amino acid sequence. The y-axis height varies with the abundance of detected peptides, while the x-axis corresponds to amino acid positions in BSA. (B) Heat map of PSMs differences for the LKH556-571 peptide cluster of BSA. The peptide sequence shown corresponds to the AMDH-modified peptide containing the modification (C18H30NO) on the lysine residue. PSMs were quantified with posterior error probability (PEP) values of <0.01. Two independent experiments are labeled as “-1” and “-2” after each sample name.



102

103 Supplementary Fig. 3 Effect of hapten density on the secondary structure and
 104 hydrogen bonding interactions of BSA by 200 ns MD simulations. (A) Secondary
 105 structure composition of BSA and AMDH-BSA conjugates C1, C3, C5, C6 over the
 106 200 ns simulation trajectory, showing percentages of α -helix, β -sheet, β -turn, and
 107 random coil at 0, 50, 100, 150, and 200 ns. (B) Number of hydrogen bonds in BSA
 108 and AMDH-BSA conjugates C1, C3, C5, and C6 over the 200 ns simulation

109 trajectory.




111


112 Supplementary Fig. 4 Influence of AMDH-BSA conjugates with varied hapten
 113 densities on CD4⁺/CD8⁺ T cells ratio and splenocytes proliferation.(A) CD4⁺/CD8⁺ T
 114 cells ratio in splenic lymphocytes from mice immunized with C1, C3, C5, C6, C8, or
 115 PBS. (B) OD₄₅₀ of splenocytes proliferation after treatment with 50 µg/mL
 116 AMDH-BSA conjugates C1, C3, C5, C6, C8, or PBS for 72 h; (C) OD₄₅₀ of
 117 splenocyte proliferation after treatment with AMDH-BSA conjugates in the presence
 118 of 10 µg/mL ConA (T cell stimulant). (D) OD₄₅₀ of splenocyte proliferation after
 119 treatment with AMDH-BSA conjugates in the presence of 12.5 µg/mL LPS (B cell
 120 stimulant). * p < 0.05, * * p < 0.005, * * * p < 0.001, * * * *p < 0.0001. Means
 121 and standard deviations are displayed (n=3 mice/group). Statistical significance was
 122 determined by ANOVA with multiple comparison testing among all groups except the

PBS

group.



Supplementary Fig. 5 AMDH-BSA-specific, BSA-specific, and AMDH-specific antibody titers of antisera from vaccinated mice on (A) day 7, (B) day 21 and (C) day 49. (D) AMDH-specific IgG3 and IgA subclasses OD₄₅₀ values in antisera from immunized mice on day 28, determined by nc-ELISA. Means and standard deviations are displayed (n=6-8 mice/group).



Supplementary Fig. 7 Synthesis and characterization of hapten AMDH. (A) Synthetic routes of AMDH. Reaction conditions: (i) ethyl bromoacetate, K_2CO_3 , DMF, 60 °C, 16 h; (ii) NaOH, EtOH/H₂O, 1 h, then HCl to pH 5. (B) The mass spectrum of AMDH. The observed molecular ion $[M-H]^-$ at m/z 292 is consistent with the calculated mass ($C_{18}H_{30}NO_2^-$, 292). (C) The 1H NMR spectrum of AMDH in DMSO- d_6 . (D) The ^{13}C NMR spectrum of AMDH in DMSO- d_6 .

145 Supplementary Table 1. Molecular descriptors of AMD and AMDH

Analytes	Molecular Properties						
	MW ^a	V _m ^b	E ^c	μ ^d	SA ^e	MPI ^f	PSA ^g
	(g/mol)	(Å ³)	(kcal/mol)	(D)	(Å ²)	(kcal/mol)	(Å ²)
AMD	151.25	213.65	-446.03	1.30	308.21	5.82	25.68 (13.56 %)
AMDH	293.45	410.72	-909.74	2.23	574.45	7.25	72.83 (19.92%)

146 ^a MW: molecular weight; ^b V_m:Molar volume; ^c Single Point Energy; ^d Dipole
147 Moment; ^e SA: Solvent Accessible Surface Area; ^f Molecular Polarizability Index; ^g
148 Polar Surface Area.

Supplementary Table 2. Analysis of hapten density in AMDH-BSA conjugates by
TNBS method

Conjugates	AMDH-BSA mole ratios	OD ₄₂₀	TNBs	
			amount of consumed amino (%)	Hapten density ^a (moles/BSA molecule)
BSA	0;1	0.68	-0.3	0
C1	5:1	0.678	0.5	0.2
C3	20:1	0.648	12.3	7.5
C5	60:1	0.632	18.8	11.5
C6	100:1	0.561	45.4	27.7
C8	500:1	0.513	66.6	40.6

^a Hapten density is calculated by percentage of consumed amino multiplying the 61 free amino acids of BSA.

153 Supplementary Table 3. The information of immunization procedures.

Immunizations	Adjuvants	Dose/mice	Immunization routes	Interval time	Blood collection	Spleen harvest
1 st	Freund's complete adjuvant	100 µg	Subcutaneous multiple injections on the neck and back	21 days	After 7 days	-
2 rd	Freund's incomplete adjuvant	100 µg	Subcutaneous multiple injections on the neck and back	21 days	After 7 days	After 7 days
3 st	Freund's incomplete adjuvant	100 µg	Subcutaneous multiple injections on the neck and back	21 days	After 7 days	After 7 days

154 - No spleen collection.

